Patents by Inventor Michael Kloft

Michael Kloft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7041798
    Abstract: The invention relates to the fractionation of plasma or serum into at least one albumin fraction and one immunoglobulin fraction by hydrophobic interaction chromatography. The fractionation is carried out using an incremental salt gradient, especially an ammonium sulfate buffer. The invention also relates to preparations obtained by using said method and to their use.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: May 9, 2006
    Assignee: Biotest Pharma GmbH
    Inventors: Norbert Kothe, Dieter Rudnick, Michael Kloft
  • Patent number: 5851524
    Abstract: The invention relates to 2 human monoclonal antibodies of sub-classes IgG1 and IgG3, against the Rhesus D antigen and to a pharmaceutical composition containing a mixture of the said antibodies, more particularly intended for the prophylaxis of the haemolytic disease of the newborn. The invention also relates to the heterohybridoma cell lines that produce these antibodies, which are filed with the "Deutsche Sammlung von Mikroorganismen und Zellkulturen" under accession numbers DSM AC 2039 and DSM AC 2040.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: December 22, 1998
    Assignees: Association pour l'Essor de la Transfusion Sanguine dans la Region du Nord, BIOTEST Pharma GmbH
    Inventors: Roland Beliard, Ulf Bethke, Dominique Bourel, Ahmed Bouzidi, Herve Broly, Peter Byrne, Magali Holuigue, Michael Kloft, Detlef Rohm
  • Patent number: 5164487
    Abstract: Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.
    Type: Grant
    Filed: March 15, 1991
    Date of Patent: November 17, 1992
    Assignee: Biotest Pharma GmbH
    Inventors: Norbert Kothe, Dieter Rudnick, Detlef Piechaczek, Herwald Klein, Detlef Rohm, Michael Kloft
  • Patent number: 5041537
    Abstract: To provide a simple method of preparing biologically active transferrin that can be employed on an industrial scale and that will result in extremely pure and natural transferrin containing no viruses and appropriate for both in-vitro and in-vivo applications, the .gamma.-globulins are precipitated from the fraction containing the transferrin, the precipitant is removed from the residual liquid by ultrafiltration or gel filtration, the liquid is adjusted to a prescribed ionic concentration and protein concentration and (a) treated with .beta.-propiolactone and the solution is subjected to ultraviolet radiation or (b) treated with specific detergents and subjected to ion-exchange chromatography, and the transferrin is concentrated and filtered sterile.
    Type: Grant
    Filed: September 27, 1988
    Date of Patent: August 20, 1991
    Assignee: Biotest Pharma GmbH
    Inventors: Ulf Bethke, Norbert Kothe, Dieter Rudnick, Wolfgang Moller, Michael Kloft
  • Patent number: 4965068
    Abstract: The present invention involves a polyvalent hyperimmunoglobulin preparation having activity against gram negative and gram positive bacteria. Such a polyvalent hyperimmunoglobulin preparation is prepared from plasma, serum or whole blood from donors. Donor selection is based upon titer against E. coli J5 antigen or against lipid A antigen.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: October 23, 1990
    Assignee: Biotest Pharma GmbH
    Inventors: Wolfgang Stephan, Herbert Dichtelmuller, Michael Kloft
  • Patent number: 4654344
    Abstract: 2-Aryltetraazaindenes of the formula ##STR1## wherein --A-- is --N.dbd.CH--CN.dbd.N-- or --CH.dbd.N--N.dbd.CH--, Ar is unsubstituted phenyl or phenyl mono-, di- or tri-substituted by hydroxyl, mercapto, dialkylamino, trifluoromethyl and/or --Z--R groups, Z is --O--, --S-- or --SO-- and R is alkyl, alkenyl, alkynyl or cyanomethyl, the alkyl, alkenyl and alkynyl groups each having up to 5 C atoms, and their physiologically acceptable salts, exhibit blood pressure, myocardial contraction, and anti-ulcer activities.
    Type: Grant
    Filed: December 20, 1985
    Date of Patent: March 31, 1987
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Rochus Jonas, Michael Kloft, Hanns Wurziger, Juergen Harting, Hans J. Enenkel, Klaus-Otto Minck, Hans-Jochen Schliep
  • Patent number: 4575505
    Abstract: 2-Aryltetraazaindenes of the formula ##STR1## wherein --A-- is --N.dbd.CH--CH.dbd.N-- or --CH.dbd.N--N.dbd.CH--, Ar is unsubstituted phenyl or phenyl mono-, di- or trisubstituted by hydroxyl, mercapto, dialkylamino, trifluoromethyl and/or --Z--R groups, Z is --O--, --S-- or --SO-- and R is alkyl, alkenyl, alkynyl or cyanomethyl, the alkyl, alkenyl and alkynyl groups each having up to 5 C atoms, and their physiologially acceptable salts, exhibit blood pressure, myocardial contraction, and anti-ulcer activities.
    Type: Grant
    Filed: July 26, 1984
    Date of Patent: March 11, 1986
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Rochus Jonas, Michael Kloft, Hanns Wurziger, Jurgen Harting, Hans J. Enenkel, Klaus-Otto Minck, Hans-Jochen Schliep
  • Patent number: 4477454
    Abstract: 2-Aryltetraazaindenes of the formula ##STR1## wherein --A-- is --N.dbd.CH--CH.dbd.N-- or --CH.dbd.N--N.dbd.CH--, Ar is unsubstituted phenyl or phenyl mono-, di- or tri-substituted by hydroxyl, mercapto, dialkylamino, trifluoromethyl and/or --Z--R groups, Z is --O--, --S-- or --SO-- and R is alkyl, alkenyl, alkynyl or cyanomethyl, the alkyl, alkenyl and alkynyl groups each having up to 5 C atoms, and their physiologically acceptable salts, exhibit blood pressure, myocardial contraction, and anti-ulcer activities.
    Type: Grant
    Filed: May 9, 1983
    Date of Patent: October 16, 1984
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Rochus Jonas, Michael Kloft, Hanns Wurziger, Juergen Harting, Hans J. Enenkel, Klaus-Otto Minck, Hans-Jochen Schliep